| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A Colao, L F S Grasso, M Di Cera, P Thompson-Leduc, W Y Cheng, H C Cheung, M S Duh, M P Neary, A M Pedroncelli, R Maamari, R Pivonell. Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study. Journal of endocrinological investigation. vol 43. issue 4. 2020-12-09. PMID:31741320. |
achieving biochemical control (normalization of insulin-like growth factor-1 [igf-1] and growth hormone [gh]) is a key goal in acromegaly management. |
2020-12-09 |
2023-08-13 |
Not clear |
| I C M Pelsma, K M J A Claessen, P E Slagboom, D van Heemst, A M Pereira, H M Kroon, Y F M Ramos, M Kloppenburg, N R Biermasz, I M Meulenbel. Variants of FOXO3 and RPA3 genes affecting IGF-1 levels alter the risk of development of primary osteoarthritis. European journal of endocrinology. vol 184. issue 1. 2020-11-30. PMID:33112260. |
pathologically high growth hormone (gh) and insulin-like growth factor-1 (igf-1) levels in patients with acromegaly are associated with arthropathy. |
2020-11-30 |
2023-08-13 |
Not clear |
| Seung Hyun Kim, Namo Kim, Kyeong Tae Min, Eui Hyun Kim, Hanseul Oh, Seung Ho Cho. Sleep disturbance and delirium in patients with acromegaly in the early postoperative period after transsphenoidal pituitary surgery. Medicine. vol 99. issue 45. 2020-11-25. PMID:33158000. |
sleep disturbance is a common comorbidity among patients with acromegaly [patients with growth hormone (gh)-secreting tumor] due to somatotropic axis change and sleep apnea. |
2020-11-25 |
2023-08-13 |
Not clear |
| Sylvère Störmann, Jochen Schopoh. Drug treatment strategies for secondary diabetes in patients with acromegaly. Expert opinion on pharmacotherapy. vol 21. issue 15. 2020-11-16. PMID:32633582. |
acromegaly is a rare disease due to oversecretion of growth hormone (gh). |
2020-11-16 |
2023-08-13 |
Not clear |
| Sylvère Störmann, Jochen Schopoh. Drug treatment strategies for secondary diabetes in patients with acromegaly. Expert opinion on pharmacotherapy. vol 21. issue 15. 2020-11-16. PMID:32633582. |
a distinct medical issue in the context of acromegaly is diabetes: it can be a complication as a consequence of gh excess and its mediators, but it can also result from treatment of acromegaly. |
2020-11-16 |
2023-08-13 |
Not clear |
| Amelia Rogozinski, Adrian F Daly, Adriana Reyes, Alejandra Furioso, Albert Beckers, Alicia Lowenstei. Differentiated thyroid carcinoma in sporadic and familial presentations of acromegaly: A case series. Annales d'endocrinologie. vol 81. issue 5. 2020-11-11. PMID:32822652. |
in acromegaly, chronic growth hormone (gh) and insulin-like growth factor-1 (igf-1) exacerbate comorbidities in multiple organs. |
2020-11-11 |
2023-08-13 |
Not clear |
| Vikram Singh Shekhawat, Shobhit Bhansali, Pinaki Dutta, Kanchan Kumar Mukherjee, Kim Vaiphei, Rakesh Kochhar, Saroj K Sinha, Naresh Sachdeva, Anura V Kurpad, Kishor Bhat, Sunder Mudaliar, Anil Bhansal. Glucose-dependent Insulinotropic Polypeptide (GIP) Resistance and β-cell Dysfunction Contribute to Hyperglycaemia in Acromegaly. Scientific reports. vol 9. issue 1. 2020-10-27. PMID:30948746. |
chronic gh excess induces an equipoise insulin resistance in patients of acromegaly irrespective of their glycaemic status. |
2020-10-27 |
2023-08-13 |
Not clear |
| Yakun Yang, Song Han, Zuocheng Yang, Pengfei Wang, Chang-Xiang Yan, Ning Li. Increased serum nesfatin-1 levels in patients with acromegaly. Medicine. vol 99. issue 40. 2020-10-19. PMID:33019423. |
however, there was no published data about nesfatin-1 levels in acromegaly.we evaluated serum nesfatin-1 levels in 13 patients with acromegaly at baseline and postoperatively, and in 21 age- and body mass index (bmi)-matched healthy subjects.compared with the healthy subjects, patients with acromegaly had significantly increased levels of serum insulin, high-density lipoprotein cholesterol, triglyceride, and growth hormone (gh). |
2020-10-19 |
2023-08-13 |
human |
| Yakun Yang, Song Han, Zuocheng Yang, Pengfei Wang, Chang-Xiang Yan, Ning Li. Increased serum nesfatin-1 levels in patients with acromegaly. Medicine. vol 99. issue 40. 2020-10-19. PMID:33019423. |
while a successful surgery decreased serum gh levels, the serum nesfatin-1 levels did not change in acromegaly (p = .965). |
2020-10-19 |
2023-08-13 |
human |
| Yakun Yang, Song Han, Zuocheng Yang, Pengfei Wang, Chang-Xiang Yan, Ning Li. Increased serum nesfatin-1 levels in patients with acromegaly. Medicine. vol 99. issue 40. 2020-10-19. PMID:33019423. |
however, increased serum gh levels were positively correlated with tumors' size (p = .023) and mutant p53 proteins expression (p = .028).circulating nesfatin-1 was increased in acromegaly, which was involved in metabolism regulation. |
2020-10-19 |
2023-08-13 |
human |
| Abhijeet Gummadavelli, Catherine Dinauer, Declan McGuone, Eugenia M Vining, E Zeynep Erson-Omay, Sacit Bulent Oma. Large-scale second-hit AIP deletion causing a pediatric growth hormone-secreting pituitary adenoma: Case report and review of literature. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. vol 78. 2020-10-05. PMID:32336638. |
gigantism (early-onset acromegaly) is a rare pediatric disorder caused by a growth hormone (gh)-secreting pituitary adenoma. |
2020-10-05 |
2023-08-13 |
Not clear |
| Melissa H Lee, Penelope McKelvie, Balasubramanian Krishnamurthy, Yi Yuen Wang, Carmela Caput. An intrasellar pituitary adenoma-gangliocytoma presenting as acromegaly. Endocrinology, diabetes & metabolism case reports. vol 2017. 2020-10-01. PMID:28469929. |
most cases of acromegaly are due to growth hormone (gh)-secreting pituitary adenomas arising from somatotroph cells. |
2020-10-01 |
2023-08-13 |
Not clear |
| Masato Hojo, Ryota Ishibashi, Hiroshi Arai, Susumu Miyamot. Granulomatous hypophysitis caused by Rathke's cleft cyst mimicking a growth hormone-secreting pituitary adenoma. Asian journal of neurosurgery. vol 12. issue 2. 2020-10-01. PMID:28484553. |
neuroradiological and endocrinological evaluations showed abnormal findings consistent with acromegaly: magnetic resonance imaging demonstrated a pituitary mass lesion, and gh and insulin-like growth factor i levels were markedly elevated, and gh levels were not suppressed in oral glucose tolerance test. |
2020-10-01 |
2023-08-13 |
Not clear |
| Per Dahlqvist, Rupert Spencer, Pedro Marques, Mary N Dang, Camilla A M Glad, Gudmundur Johannsson, Márta Korbonit. Pseudoacromegaly: A Differential Diagnostic Problem for Acromegaly With a Genetic Solution. Journal of the Endocrine Society. vol 1. issue 8. 2020-10-01. PMID:29264563. |
however, a few conditions present with some aspects of acromegaly or gigantism but without growth hormone (gh) excess. |
2020-10-01 |
2023-08-13 |
Not clear |
| Robert D'Arcy, C Hamish Courtney, Una Graham, Steven Hunter, David R McCance, Karen Mulla. Twenty-four-hour growth hormone profiling in the assessment of acromegaly. Endocrinology, diabetes & metabolism. vol 1. issue 1. 2020-10-01. PMID:30815544. |
recent guidelines recommend insulin-like growth factor (igf-1), random growth hormone (gh) and nadir gh on an oral glucose tolerance test (ogtt) for assessment of acromegaly. |
2020-10-01 |
2023-08-13 |
Not clear |
| Ł Mizera, M Elbaum, J Daroszewski, M Bolanowsk. CARDIOVASCULAR COMPLICATIONS OF ACROMEGALY. Acta endocrinologica (Bucharest, Romania : 2005). vol 14. issue 3. 2020-10-01. PMID:31149285. |
relation between acromegaly and coronary artery disease is controversial as it seems to be connected rather with classical cardiovascular risk factors than gh and igf-1 overexpresion. |
2020-10-01 |
2023-08-13 |
Not clear |
| Shahrzad Mohseni, Maryam Aboeerad, Farshad Sharifi, Seyed Mohammad Tavangar, Mohammadreza Mohajeri-Tehran. Associations of Ki-67 Labeling Index with Clinical and Paraclinical Features of Growth Hormone-Secreting Pituitary Adenomas: A Single Center Report from Iran. International journal of endocrinology and metabolism. vol 17. issue 2. 2020-10-01. PMID:31372169. |
acromegaly is a rare disorder resulting from benign growth hormone (gh)-secreting pituitary adenomas in 90% of the cases. |
2020-10-01 |
2023-08-13 |
Not clear |
| b' Betina Biagetti, J R Herance, Roser Ferrer, Anna Aulinas, Martina Palomino-Sch\\xc3\\xa4tzlein, Jordi Mesa, J P Casta\\xc3\\xb1o, Raul M Luque, Rafael Sim\\xc3\\xb. Metabolic Fingerprint of Acromegaly and its Potential Usefulness in Clinical Practice. Journal of clinical medicine. vol 8. issue 10. 2020-10-01. PMID:31561638.' |
insulin-like growth factor-1 (igf-1) and growth hormone (gh) levels are the main targets for monitoring acromegaly activity, but they are not in close relationship with the clinical course of the disease and the associated comorbidities. |
2020-10-01 |
2023-08-13 |
Not clear |
| Kristin Godang, Tove Lekva, Kjersti Ringvoll Normann, Nicoleta Cristina Olarescu, Kristin Astrid Berland Øystese, Anders Kolnes, Thor Ueland, Jens Bollerslev, Ansgar Hec. Hip Structure Analyses in Acromegaly: Decrease of Cortical Bone Thickness After Treatment: A Longitudinal Cohort Study. JBMR plus. vol 3. issue 12. 2020-10-01. PMID:31844828. |
long-standing growth hormone (gh) excess causes the skeletal clinical signs of acromegaly with typical changes in bone geometry, including increased cortical bone thickness (cbt). |
2020-10-01 |
2023-08-13 |
Not clear |
| Gudmundur Johannsson, Martin Bidlingmaier, Beverly M K Biller, Margaret Boguszewski, Felipe F Casanueva, Philippe Chanson, Peter E Clayton, Catherine S Choong, David Clemmons, Mehul Dattani, Jan Frystyk, Ken Ho, Andrew R Hoffman, Reiko Horikawa, Anders Juul, John J Kopchick, Xiaoping Luo, Sebastian Neggers, Irene Netchine, Daniel S Olsson, Sally Radovick, Ron Rosenfeld, Richard J Ross, Katharina Schilbach, Paulo Solberg, Christian Strasburger, Peter Trainer, Kevin C J Yuen, Kerstin Wickstrom, Jens O L Jorgense. Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocrine connections. vol 7. issue 3. 2020-09-30. PMID:29483159. |
the growth hormone research society (grs) convened a workshop in 2017 to evaluate clinical endpoints, surrogate endpoints and biomarkers during gh treatment of children and adults and in patients with acromegaly. |
2020-09-30 |
2023-08-13 |
Not clear |